Published in
Springer Nature [academic journals on nature.com], Leukemia, 10(35), p. 3007-3011, 2021
DOI: 10.1038/s41375-021-01298-y
Links
Tools
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Journal article published in 2021 by
Hans Salwender 
,
Ahmet Elmaagacli,
Maximilian Merz,
Kaya Miah ,
Axel Benner,
Mathias Haenel,
Christian Jehn,
Elias K. Mai ,
Uta Bertsch,
Igor W. Blau,
Christof Scheid,
Dirk Hose,
Anja Seckinger,
Anna Jauch,
Marc S. Raab
and other authors.
,
Ahmet Elmaagacli,
Maximilian Merz,
Kaya Miah ,
Axel Benner,
Mathias Haenel,
Christian Jehn,
Elias K. Mai ,
Uta Bertsch,
Igor W. Blau,
Christof Scheid,
Dirk Hose,
Anja Seckinger,
Anna Jauch,
Marc S. Raab
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 